TY - JOUR U1 - Zeitschriftenartikel, wissenschaftlich - nicht begutachtet (unreviewed) A1 - Alzagameem, Abla A1 - Bergs, Michel A1 - Witzler, Markus A1 - El Khaldi-Hansen, Basma A1 - Klein, Stephanie E. A1 - Hielscher, Dorothee A1 - Kamm, Birgit A1 - Kreyenschmidt, Judith A1 - Tobiasch, Edda A1 - Schulze, Margit T1 - Lignin-Derived Biomaterials for Drug Release and Tissue Engineering N2 - Renewable resources gain increasing interest as source for environmentally benign biomaterials, such as drug encapsulation/release compounds, and scaffolds for tissue engineering in regenerative medicine. Being the second largest naturally abundant polymer, the interest in lignin valorization for biomedical utilization is rapidly growing. Depending on resource and isolation procedure, lignin shows specific antioxidant and antimicrobial activity. Today, efforts in research and industry are directed toward lignin utilization as renewable macromolecular building block for the preparation of polymeric drug encapsulation and scaffold materials. Within the last five years, remarkable progress has been made in isolation, functionalization and modification of lignin and lignin-derived compounds. However, literature so far mainly focuses lignin-derived fuels, lubricants and resins. The purpose of this review is to summarize the current state of the art and to highlight the most important results in the field of lignin-based materials for potential use in biomedicine (reported in 2014–2018). Special focus is drawn on lignin-derived nanomaterials for drug encapsulation and release as well as lignin hybrid materials used as scaffolds for guided bone regeneration in stem cell-based therapies. KW - multivariate data processing KW - stem cells KW - tissue engineering KW - scaffolds KW - biomaterial KW - hydrogel KW - bone regeneration KW - lignin KW - drug release KW - osteogenesis UN - https://nbn-resolving.org/urn:nbn:de:hbz:1044-opus-38483 U6 - https://doi.org/10.20944/preprints201807.0241.v1 DO - https://doi.org/10.20944/preprints201807.0241.v1 PB - MDPI CY - Basel ER -